Combination chemo may be effective against myelodysplastic syndrome
A very small phase I study from researchers at the Cleveland Clinic's Taussig Cancer Institute suggests that there may be some future justification to using combination chemotherapy to treat myelodysplastic syndrome (MDS).
Currently there are three FDA-approved drugs to treat MDS and, unlike in other chemotherapy regimens, treatment guidelines call for the use of only one. This study examined the efficacy and toxicity of combining two into a single treatment.
BLOOD CANCER SUBTYPE(S) IN QUESTION
High-risk myelodysplastic syndrome
COHORT
Patients: 18
Median age: 68
RESEARCH FINDINGS
The combination of lenalidomide (Revlimid) and azacitidine (Vidaza) produced a response in 12 patients (67%) and a complete response in 8 (44%). The median duration of response was eight months. Eight of the responsive patients either relapsed or had their disease progress, with two progressing into acute myeloid leukemia (AML).
PUBLICATION & SOURCES
This study was published online in the Journal of Clinical Oncology .
Source: MedPageToday
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
